ImmunoGen adds Merck's Keytruda to its ovarian cancer trials
ImmunoGen Inc. and Merck & Co. Inc. entered into an trial collaboration to investigate the combination of Merck's marketed immunotherapy Keytruda (pembrolizumab) with Immunogen's mirvetuximab soravtansine for ovarian cancer.
- Trial Collaborations
- R&D (No Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.